Comparative Pharmacology
Head-to-head clinical analysis: TRAVATAN Z versus YUVEZZI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRAVATAN Z versus YUVEZZI.
TRAVATAN Z vs YUVEZZI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective FP prostanoid receptor agonist; increases uveoscleral outflow of aqueous humor by binding to FP receptors in the ciliary muscle and trabecular meshwork, leading to matrix metalloproteinase activation and remodeling of extracellular matrix.
YUVEZZI is not a recognized drug. No mechanism available.
One drop in the affected eye(s) once daily in the evening. Ophthalmic solution 0.004% (travoprost 0.04 mg/mL).
150 mg orally twice daily
None Documented
None Documented
Terminal elimination half-life is 45 minutes; due to rapid hydrolysis to active acid, the clinical effect duration is longer than the half-life suggests.
Terminal elimination half-life of 8–12 hours; permits twice-daily dosing in most indications
Primarily eliminated via hepatic metabolism; renal excretion of metabolites accounts for approximately 20% of the dose; fecal excretion is minimal.
Renal: 70% unchanged; biliary/fecal: 30% as metabolites
Category C
Category C
Prostaglandin Analog
Prostaglandin Analog